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Abstract
Purpose This paper examines the scope of anorectics in counterfeit weight-reducing formulations and provides insight into 
the present state of research in determining such adulterants. Analytical techniques utilised in profiling adulterants found in 
slimming products, including limitations and mitigation steps of these conventional methods are also discussed. The current 
legal status of the anorectics and analogues routinely encountered in non-prescription slimming formulations is also explored.
Methods All reviewed literature was extracted from Scopus, Web of Science, PubMed, and Google Scholar databases using 
relevant search terms, such as, ‘counterfeit drugs’, ‘weight loss drugs’, ‘weight-reducing drugs’, ‘slimming drugs’, ‘anorectic 
agents’, and ‘counterfeit anorexics’. Legislation related to anorectics was obtained from the portals of various government 
and international agencies.
Results Anorectics frequently profiled in counterfeit slimming formulations are mostly amphetamine derivatives or its 
analogues. Five routinely reported pharmacological classes of adulterants, namely anxiolytics, diuretics, antidepressants, 
laxatives, and stimulants, are mainly utilised as coadjuvants in fake weigh-reducing formulations to increase bioavailabil-
ity or to minimise anticipated side effects. Liquid and gas chromatography coupled with mass spectrometric detectors are 
predominantly used techniques for anorectic analysis due to the possibility of obtaining detailed information of adulterants. 
However, interference from the complex sample matrices of these fake products limits the accuracy of these methods and 
requires robust sample preparation methods for enhanced sensitivity and selectivity. The most common anorectics found in 
counterfeit slimming medicines are either completely banned or available by prescription only, in many countries.
Conclusions Slimming formulations doped with anorectic cocktails to boost their weight-reducing efficacy are not uncom-
mon. Liquid chromatography combined with mass spectrometry remains the gold standard for counterfeit drug analysis, 
and requires improved preconcentration methods for rapid and quantitative identification of specific chemical constituents. 
Extensive method development and validation, targeted at refining existing techniques while developing new ones, is expected 
to improve the analytical profiling of counterfeit anorectics significantly.
Keywords Anorectics · Counterfeit weight loss formulations · Adulterants in slimming products · Amphetamine 
derivatives · Antihyperglycemic agents · LC–MS/MS
Introduction
Counterfeit pharmaceutical products represent an enormous 
global burden, and their sales have seen a tremendous surge 
in recent years, with its attendant threat to human health and Supplementary Information The online version contains 
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public safety [1, 2]. An estimated 10% of the global pharma-
ceutical market consists of fake and substandard drugs [3]. 
Many countries in sub-Saharan Africa, Southeast Asia and 
Latin America, serve as fertile grounds, where about 30 to 
60% of sold medicines are fraudulent [4]. The Pharmaceuti-
cal Security Institute (PSI) based on a seventeen consecutive 
year data on counterfeiting, recognized a permanent increase 
in case reports as well as an extensive growth in the manu-
facture, distribution, transportation, and international trade 
in fake medicines [5].
Any kind of medications that are in high demand by con-
sumers and with profitable market prospects are targets for 
counterfeiting [6]. Due to the potential for huge profits in 
their markets, Europe (especially the United Kingdom) and 
the United States, have recorded an increase in seized coun-
terfeit therapeutics, mostly facilitated by Internet transac-
tions [5, 7]. As a result of the increasing demand for cheap 
medicines and low production cost, counterfeit pharmaceu-
tical trade continues to be a massively lucrative business 
with sophisticated global networks. For instance, in a global 
crackdown by Interpol [8], about “$41-million haul of illegal 
pharmaceuticals being sold online” were confiscated, with 
9.9 million doses of counterfeit drugs seized in the United 
Kingdom [7] as reported by the Medicines and Healthcare 
Products Regulatory Agency (MHRA). Fake medications 
advertised for treatment of erectile dysfunction, hair loss 
and slimming (weight loss) were the frequently encoun-
tered drugs in the seized hauls. The United Nations Office 
on Drugs and Crime (UNODC) recognizes counterfeit medi-
cines as a global public health threat [9] with a projected sale 
of approximately $200 billion in 2013 [10, 11].
Typically adulterated medicines with extensive global 
reach include those for sleeping disorders [12], non-steroi-
dal anti-inflammatory drugs, antibiotics [13–15], anticancer 
drugs [16, 17], erectile dysfunction drugs [18, 19] and ano-
rectics [20–22]. Anorectics (or anorexics) refer to medicines 
or dietary supplements used for weight-loss purposes [23]. 
Medicines sold over-the-counter and from Internet sources 
adulterated with anorectics and/or their analogues or metab-
olites have been reported [24–29]. Similarly, phytotherapeu-
tic (i.e., plant-based) formulations that are deemed “natural 
product” alternative treatment for obesity have been dem-
onstrated to contain non-declared anorectics and adjuvants 
that boost their efficacy [24, 30–35]. There are, however, 
scarce reports that systematically review data from a foren-
sic perspective. This paper, therefore, explores the current 
evidence related to anorectics in counterfeit weight-reducing 
formulations, including their forensic profiling, analytical 
techniques and legal status.
Collection of the literature
Literature search, data selection and extraction were per-
formed in Scopus, Web of Science and PubMed databases 
(2000–2019) for relevant peer-reviewed original articles. 
The search terms used were ‘counterfeit drugs’, ‘weight 
loss drugs’, ‘weight-reducing drugs’, ‘slimming drugs’, 
‘anorectic agents’, and ‘counterfeit anorexics’. Google 
Scholar database search was used as an additional screen-
ing of initially identified publications to expand the source 
of data as well as to ensure the completeness of the search 
strategy. Current legislation on the anorectics was obtained 
from online portals/repositories of international statutory 
bodies and country-specific agencies.
Anorectics in counterfeit weight loss 
products
An anorectic or anorexic is a general term used to describe 
any agent, such as drugs, medicines and/or dietary supple-
ments, which is used for weight loss purposes. For instance, 
de Carvalho et al. [25] reported that about 80% of ampheta-
mines produced legally are utilized for weight loss therapies. 
A significant factor that has accounted for the recent rise in 
anorectic use is obesity [36]. This condition, considered as 
a global public health problem [37], affects millions of indi-
viduals. Since medications for management and treatment 
of obesity are mostly prescription only in many countries 
[38], online pharmacies and unreliable Internet sources serve 
as an off-prescription route to purchase slimming products 
[22, 39]. Also, misleading advertisements, entrenched by 
the modern craze for the “ideal figure” beauty standards 
propagated by the mainstream media have contributed to 
unbridled view and quest of people for slimming products 
[3]. Counterfeiting contravenes the legislations of many 
countries [1, 40], because such formulations tend to have 
constituents inconsistent with their real declared and regis-
tered ones. The presence of these falsely declared active ano-
rectic ingredients, therefore, makes their effects on human 
body random and unpredictable [32]. Apart from the adverse 
health effects and deaths associated with the toxic additives, 
such counterfeiting poses threats to pharmaceutical indus-
tries, as well as the economy and health care systems of 
countries [2, 10]. Moreover, the unpredictability regarding 
the chemicals that can be present as undeclared constituents 
of fake formulations requires the development of sensitive 
and selective analytical methods for their identification and 
quantification.
Anorectics agents found as adulterants in drugs, medi-
cines and/or dietary supplements induce loss of appetite, 
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minimize intestinal fat (lipid) absorption as well as 
increasing the sensing of satiety [24]. Although there is a 
category of specifically designed drugs called anorectics 
(e.g., phentermine) mainly for the management of obesity, 
several other drug classes, mostly centrally acting ones, 
such as the amphetamines and similar sympathomimetic 
amines, have anorectic properties. The pharmacokinetics 
of important anorectic agents (Fig. 1) commonly encoun-
tered as adulterants in counterfeit drugs are discussed here.
Sibutramine
Sibutramine (N-(1-(1-(4-chlorophenyl)-cyclobutyl)-
3methylbutyl)-N, N-dimethylamine hydrochloride) (trade 
names Meridia® in the USA, Reductil® in Europe and 
Australia), an amphetamine derivative, is an anorectic drug, 
which acts by inhibiting serotonin (5-hydroxytryptamine: 
5-HT), norepinephrine, and to a small extent, dopamine 
reuptake [41–43]. Following the inhibition of these neuro-
transmitters, an enhanced sense of satiety and decrease in 
appetite, lead to reduced food intake [44]. Through thermo-
genic effects in basal and fed state, sibutramine and its two 
pharmacologically active metabolites, N-monodesmethyl 
and N-di-desmethyl sibutramine, have also been reported 
to increase energy expenditure [45–49]. Weight loss is as 
a result of the antiatherogenic effect of sibutramine, which 
enhances insulin resistance, metabolism of glucose, and dys-
lipidemia. Sibutramine is a routine adulterant in slimming 
products, especially in phytotherapeutic (herbal) food sup-
plements [18, 24, 35].
Fenfluramine
Fenfluramine (ethyl({1-[3-(trifluoromethyl) phenyl] propan-
2-yl}) amine) is another anorectic associated with counter-
feit slimming pharmaceuticals. Like sibutramine, it is also 
an amphetamine derivative and a serotonin reuptake inhibi-
tor. It was mainly prescribed for the management of obesity 
[50]. The drug and its metabolites/analogues (dexfenflu-
ramine, N-nitrosofenfluramine) act by affecting the brain’s 
metabolism such that serotogenic transmission is enhanced 
in the hypothalamic feeding and satiety centres leading to 
reduced calorie intake [51]. Fenfluramine and its analogues 
are major synthetic chemicals found as adulterants in coun-
terfeit weight loss medicines, with reported severe pulmo-
nary hypertension and deaths [22, 52].
Metformin
Metformin (1-carbamimidamido-N, N-dimethylmethanimid-
amide hydrochloride) is a biguanide antihyperglycemic drug 
used to manage type 2 diabetes [53]. It is pharmacologi-
cally different in action to other classes of antihyperglycemic 
agents. It enhances glucose tolerance in type 2 diabetic 
patients by reducing hepatic glucose production, lower-
ing intestinal absorption of glucose, increasing peripheral 
glucose uptake and improving insulin sensitivity [54–56]. 
Metformin is continuously detected in fake slimming formu-
lations [57], because unlike sulfonylureas, it does not cause 
hypoglycaemia nor hyperinsulinemia even when adminis-
tered alone in healthy subjects or patients with type 2 dia-
betes [58]. In some instances, however, metformin, like its 
withdrawn structural analogues buformin and phenformin, is 
known to cause lactic acidosis as a result of the very minimal 
liver uptake of serum lactate which is a required substrate of 
gluconeogenesis [59, 60].
Phentermine
Phentermine (α,α-dimethylphenethylamine), traded under 
brand names Adipex, Adipex-P, Fastin, Lonamin, Phenter-
cot, Phentride and Pro-Fast [61–64] is the oldest and com-
monest anorectic prescribed for the management of obesity 
[65]. It is a noradrenergic sympathomimetic agent approved 
by the FDA for short-term (< 12 weeks) treatment in com-
bination with regular exercise and reduction in caloric diet, 
for the treatment of obesity [66]. However, phentermine 
has been used off-label as a long-term treatment for obesity 
without any serious adverse effects [67]. Initially ascribed as 
a central nervous system stimulant which triggers the release 
of norepinephrine in the hypothalamus [68], recent evidence 
suggests that phentermine inhibits the reuptake of norepi-
nephrine and dopamine [68]. Subsequently, this suppresses 
appetite [69] and decreases body weight by reducing food 
intake and increasing resting energy expenditure [70, 71]. 
Phentermine is a key synthetic drug often illegally added to 
herbal slimming formulations and nutraceutical supplements 
[72, 73] to boost their efficacy. The use of this anorectic in 
such formulations has been associated with some adverse 
cardiovascular effects, such as primary pulmonary hyper-
tension, palpitations, tachycardia, ischemic events [69], and 
dry mouth.
Amfepramone (diethylpropion)
Amfepramone (2-diethylaminopropiophenon) stimulates the 
central nervous system to suppress appetite by increasing the 
release of catecholamines (dopamine and noradrenaline) in 
the hypothalamus and further limits their reuptake [74]. Sub-
sequently, the drug is used as a short-term anorectic agent 
for the treatment of obesity [75]. Amfepramone is the most 
frequently abused and illicitly trafficked pharmacological 
adulterants in herbal weight loss products worldwide [32]. 
De Carvalho et al. [76] detected levels of amfepramone in 
all 106 herbal weight loss products analyzed. Similarly, 
Almeida et al. [77] found amfepramone as an adulterant in 
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herbal weight loss products at levels of 5% in 20 samples 
examined. Nonetheless, amfepramone has been associated 
with some moderate adverse effect, such as dry mouth, 
insomnia, anxiety, irritability, constipation, headache, diz-
ziness and polydipsia [78]. The anorectic was previously 
linked to the development of pulmonary hypertension [79], 
but has since been disproved [80].
Methylphenidate
Typically sold under the label Ritalin, methylphenidate is 
a central nervous system stimulant initially utilised as an 
analeptic for reversal of barbiturate-induced coma [81]; 
however, it is currently used to treat attention-deficit hyper-
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Fig. 1  Structures of anorectics frequently found in counterfeit weight loss formulations
5Forensic Toxicology (2021) 39:1–25 
1 3
the release of stored or newly synthesized dopamine and 
inhibits reuptake by binding to the dopamine receptor [83]. 
This results in increased extracellular dopamine levels that 
facilitate slimming via suppression of appetite [81] as dem-
onstrated by the sudden weight loss in ADHD patients [84]. 
The stimulant has been shown to increase blood pressure 
with the attendant risk of cardiovascular disease and strokes 
[85]. The seemingly explosive increase in prescriptions of 
Ritalin [86] could result in the medicine being abused as a 
weight-loss drug [87], and such incidence has been reported 
on a limited scale [87].
Modafinil
Modafinil and its analogue have been detected in various 
slimming herbal products. Deconinck et al. [88] identified 
modafinil at a concentration of 0.125–1.00 mg/mL in herbal 
slimming products. Vanhee et al. [89] reported the presence 
of adrafinil, an analogue of modafinil in a food supplement 
that was submitted by the Federal Agency for Safety of the 
Food Chain (FASFC), Belgium. As a eugeroic psychostim-
ulant, modafinil (2-[(diphenylmethyl) sulfinyl] acetamide) 
sold under the brand name Provigil, is used primarily for 
the treatment of narcolepsy, shift work sleep disorder and 
obstructive sleep apnoea [90–93]. While the exact mecha-
nism is unknown, stimulating the release of norepineph-
rine, dopamine and serotonin and subsequently inhibiting 
their reuptake has been mooted [94]. Research by Makris 
et al. [95] reported improved appetite suppression following 
administration of modafinil and recommended its use for 
the treatment of obesity. Despite a lower risk of cardiovas-
cular-related adverse effects, the drug has been associated 
with moderate side effects, such as headache, nausea, diar-
rhoea, nervousness, anxiety, dyspepsia, and insomnia [96, 
97]. Recent works by Lazenka et al. [98] and Avelar et al. 
[99] have, however, shown that modafinil’s action on brain’s 
dopamine centres is identical to that of methamphetamine 
and cocaine.
Rimonabant
Rimonabant, sold under the trade name Acomplia or Zimulti 
is an anorectic, antiobesity drug. It is a selective endocan-
nabinoid  CB1 receptor antagonist that effects weight loss 
through the reduction in appetite [100]. In mature patients 
with type 2 diabetes, the drug showed some beneficial 
effects, such as glycemic control, reduced waist circumfer-
ence and weight. However, rimonabant has since been with-
drawn from the market and clinical use due to its neuropsy-
chiatric side effects, notably, the onset of suicidal tendencies 
in patients [101]. Subsequently, analogues taranabant and 
otenabant, considered as a promising treatment for obesity 
due to improved anorectic effects were discarded [102]. 
Despite the risk of significant adverse effects, ample evi-
dence indicates the availability of Acomplia, either genuine, 
counterfeited or as adulterants in weight loss formulations, 
to purchase on the Internet [103].
Mitragynine
Mitragynine is obtained from the plant Mitragyna spe-
ciosa (also known as kratom) and is the most abundant 
active alkaloid isolated from the plant, with speciogynine, 
paynantheine, and 7-hydroxymitragynine making up the 
other essential alkaloids [104]. Kratom is primarily avail-
able as a drug of abuse, and its pharmacological effects have 
been reported to be dose-dependent [105]. Stimulant effects 
and opiate-like effects are achieved in lower and higher 
doses, respectively [106, 107]. Several adverse effects have 
been documented to be associated with mitragynine use in 
humans. These include dry mouth, constipation, changes in 
urination pattern, vomiting, nystagmus, tremor, anorexia 
and weight loss [108]. Anorexia and weight loss are side 
effects which are most prominent in chronic users of the 
drug [109], and this observation has influenced the use of 
mitragynine—a psychoactive plant extract—as an anorectic 
[110]. An online market [111] that sells extracts of kratom 
with different levels of purity and/or enhancement, for 
instance, declares “there are some detractors who consider 
kratom’s long-term effects of weight loss to be an unwanted 
side effect” on the website in a concerted effort to advertise 
and encourage the use of mitragynine for slimming purposes 
among other “modern benefits”.
Other drug classes
Apart from conventional anorectics, adulterants mainly 
found in fake slimming products have been grouped into 
five pharmacological classes, namely anxiolytics, diuret-
ics, antidepressants, laxatives and other stimulants [88]. 
These drug groups are mainly utilized as coadjuvants in 
the formulations to possibly increase bioavailability or 
to minimize the various side effects, such as irritability, 
headaches, nervous depression, chemical dependence and 
unstable humour [52], associated with the use of certain 
anorectics to mostly mask the presence of anorexics.
Anxiolytic action of benzodiazepines, such as diazepam 
and alprazolam, routinely found in counterfeit slimming 
formulations is targeted at reducing the anxiety side effects 
caused by anorexics [112]. Antidepressants are a routine 
find in fake slimming pharmaceutical formulations. While 
they are mostly incorporated to counter the detrimental 
effects of the actual anorectics [25], some antidepressants 
directly facilitate weight loss. For instance, bupropion, 
a norepinephrine and dopamine reuptake inhibitor is an 
atypical antidepressant that causes the most weight loss 
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[113, 114] and frequently encountered as an adulterant in 
slimming formulas. However, the slimming action of this 
drug has been attributed to its side effects, mainly loss of 
appetite, nausea, and vomiting [115]. The FDA has, thus, 
approved bupropion for weight loss [116]. Sertraline is 
another antidepressant used as coadjuvant in fake slim-
ming products since it has been documented to effectively 
limit the nervous depression most often reported in obese 
people using anorectics [25]. Tricyclic antidepressants, 
such as amitriptyline, trimipramine, imipramine and desip-
ramine, selectively inhibit the reuptake of norepinephrine 
and to some extent, aid in the loss of weight due to this 
activity [117]. Diuretics (e.g., furosemide) and laxatives 
(e.g., phenolphthalein) are intentionally added adulterants 
to increase urine flow and intestinal motility, respectively. 
These synthetic compounds are often found as adulterants 
in herbal-based (phytotherapeutic) weight loss formulas 
[118], but their effect is not associated with a reduction in 
body fat but mainly increased loss of body water content. 
Many compounds from plant-based medicines have intrin-
sic laxative as well as diuretic properties and produce their 
deleterious effects akin to those from synthetic ones [119]. 
Therefore, the presence of undeclared laxatives or diuret-
ics in phytotherapeutic carries risks, including dehydration 
and electrolyte imbalance [120], either independently or 
as a result of interaction with other constituents within 
the formulation.
Coffee, tea, guarana or other plant extracts have been 
reported to be efficient in loss of weight processes owing 
to caffeine consumption [121, 122], although some studies 
suggest that in-depth research should be performed to dem-
onstrate the usefulness of these extracts or pure caffeine as 
food supplements for individuals who are following a diet 
[123]. Caffeine is metabolized to 3,7 dimethylxanthine (the-
obromine), 1,7 dimethylxanthine, and 1,3-dimethylxanthine 
(theophylline) by the liver, and the elimination mechanism 
depends on the initial dose of caffeine ingested.
Legal status
The legal status of anorectics is mostly determined based on 
studies that evaluate the safety, tolerability, pharmacokinet-
ics and/or toxicological profile/clinical outcome following 
the administration of a drug. For instance, due to the risk of 
heart failure, stroke and psychosis [124], sibutramine was 
banned in the United States by the Food and Drug Admin-
istration (FDA) [125], the European Union by the European 
Medicine Agency (EMA) [126], and Australia’s Therapeutic 
Goods Administration (TGA) [127]. The ban was based on 
the data from the six-year Sibutramine Cardiovascular Out-
come (SCOUT) trial with 10,742 patients which confirmed 
an increased risk of major cardiac events with the anorectic 
use [128]. Subsequently, many countries have withdrawn 
sibutramine from their markets since 2010. Similarly, fen-
fluramine was banned and withdrawn from the market by 
the FDA in 1997 [129] due to its association with rare heart-
valve disease in people who administered them as a diet pill 
[51]. Although the European Commission banned fenflu-
ramine and dexfenfluramine based on "unacceptable safety 
profile in normal conditions of use, their lack of therapeutic 
efficacy and the consequent unfavourable risk/benefit bal-
ance" [130], the decision has since been revoked by the EU’s 
General Court [131].
Due to concerns of the potential for abuse, phentermine 
has been classified as Schedule IV controlled substance 
[132]. Rimonabant, including analogous centrally acting 
weight-reducing drugs, was banned by the FDA follow-
ing the emergence of severe mood disorders [133]. Nei-
ther Mitragyna speciose nor its alkaloids fell under any 
listed schedules of the United Nations Drugs Convention 
[134, 135]. Some EU member states, however, categorize 
kratom as controlled, narcotic or “drug of concern” [134] 
while the US FDA has temporarily placed mitragynine and 
7-hydroxymitragynine under Schedule I of the Controlled 
Substances Act [136], given its direct link with death [137]. 
Mitragynine is, however, banned in Malaysia, Myanmar, and 
Australia [138]. The current legal status of the main anorec-
tics examined in this paper is presented in Table 1.
Detection of anorectics in counterfeit 
slimming products
Differentiation between known authentic and suspected 
counterfeit formulations primarily involves physical exami-
nation and comparison of features on the drugs and packag-
ing, such as texts on blister packs, packets and leaflet inserts 
[139]. This process is subjective and depends mainly on the 
experience of the analyst. Moreover, advancements in tech-
nology, which has contributed to sophistication in counter-
feiting, mean that a careful visual inspection is inadequate 
for the purpose and must be followed by chemical analytical 
methods. Several methods and technologies are available 
for the screening of suspected counterfeit pharmaceutical 
formulations. For instance, marking and coding of medicines 
and/or their packaging are increasingly being undertaken by 
manufacturers, to check counterfeiting in efforts to protect 
their brand as well as to facilitate effortless initial examina-
tions by law enforcement personnel [140]. However, fol-
lowing the discovery of a case of drug counterfeiting, it is 
prudent to obtain information on its chemical composition to 
enable assessment of potential dangers to patients or users.
For instance, an analysis of the FDA’s “tainted weight 
loss products” [141] list, which consists of over-the-counter 
(OTC) products frequently advertised as dietary supplements 
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but containing potentially harmful undeclared active ingre-
dients, gives insight to the need for robust detection of 
counterfeit anorectics. The eleven-year data, presented in 
Fig. 2a, shows an extensive number of adulterated anorectics 
on the market (total 197), with an average of 18 adulterated 
new products per year. Multiple drug classes of banned and 
legal (prescription only) anorectics were deceptively hidden 
in these products. Predominantly, either sibutramine or its 
analogues only (59%) or in combination with other drug 
classes (84%) are found as undeclared chemicals in OTC 
slimming products (Fig. 2c). Most of these fake slimming 
medicines are developed for oral administration, commonly 
as capsules (Fig. 2b).
Due to the broad range of synthetic pharmaceutical 
classes that may be found as adulterants in slimming for-
mulations, selectivity and sensitivity form the essential 
analytical requirements that must be fulfilled. Determination 
of chemical constituents of a suspected fake formulation, 
therefore, requires the vital initial step of sample preparation 
(extraction) and preconcentration using various techniques.
Sample preparation for anorectics 
in counterfeit pharmaceuticals
Despite the major advancements and production of powerful 
analytical instruments (e.g., sensors, microscopy, chroma-
tography, spectroscopy), direct sample analyses, especially 
in biological and pharmaceutical formulations samples are 
often not possible owing to factors, such as matrix inter-
ference and low analyte concentrations [169]. This neces-
sitates the use of some pretreatment steps aimed at sample 
Table 1  Legal status of selected anorectics in counterfeit formulations
Anorectic Legal status Reference(s)
Sibutramine Banned and withdrawn from markets due to the risk of 
major cardiac events
[125–127]
Fenfluramine Removed from the market by the manufacturer due to 
association with serious health problems
[142]
Phentermine Schedule IV in the US, available by prescription only 
in many countries
[132]
Metformin Available by prescription only in many countries [143]
Buformin Never approved for sale in the US, removed from mar-
kets in most countries due to increased risk of lactic 
acidosis. Available by prescription only in  Romania1, 
 Hungary2,  Taiwan3 and  Japan4
[144, 145]1, [146]2, [147]3, [147]4
Phenformin Withdrawn from the market as an antidiabetic drug due 
to the high risk of fatal lactic acidosis
[148]
Rimonabant Never approved in the US, withdrawn from the market 
globally due to concerns over dangerous psychologi-
cal side effects, including suicidality and depression
[101, 133]
Amfepramone (diethylpropion) Classified as Schedule IV controlled substance in the 
US and  Canada1, Class C drug in the  UK2, and avail-
able by prescription only in  Australia3 and  Germany4
[149]1, [150]2, [151]3, [152]4
Methylphenidate Designated Schedule II  internationally1, the 
 US2, Schedule III in  Canada3 and Schedule 8 in 
 Australia4. Controlled substance Class B in the  UK5, 
Class B2 in New  Zealand6, List II controlled sub-
stance of medical value in  Sweden7, and controlled 
Psychotropics in  Japan8
[153]1, [154]2, [155]3, [156]4, [157]5, [158]6, [159]7, 
[160]8
Modafinil Classified as Schedule IV controlled substance in the 
 US1 and  Sweden2, Schedule 4 prescription-only 
medicine in  Australia3, Class I and Schedule 1 
psychotropic drug in  China4 and  Japan5, respectively, 
and Schedule II controlled substance in the same 
class as morphine and cocaine in  Russia6
[149]1, [161]2, [162]3, [163]4 [160]5, [164]6
Mitragynine (plant / alkaloids) Not listed under any schedules of the  UNDC1; not 
approved for any medical use and under Schedule 
I consideration in the  US2, controlled as Narcotic 
in  Australia3 and New  Zealand4; controlled as 
Designated substance in  Japan5. Plant controlled in 
 Europe6 and prohibited in the  UK7
[134]1, [165]2, [162]3, [166]4, [167]5, [110]6, [168]7
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cleanup, enrichment, as well as signal enhancement. Notable 
(but not exhaustive) pretreatment methods that have found 
application in preconcentration and cleanup of analytes 
prior to instrumental analysis in forensic investigations 
include: filtration with polyvinylidene difluoride membrane 
syringe [26, 27, 103], polytetrafluoroethylene [24] or cel-
lulose acetate [170] filter following sample dissolution in 
organic solvent and sonication; solid-phase extraction (SPE) 
[171]; liquid–liquid extraction (LLE) [28], microwave-
assisted extraction (MAE) [172], liquid-phase microextrac-
tion (LPME) [173, 174] and solid-phase micro-extraction 
(SPME) [175].
Sporkert and Pragst [176] used headspace SPME (HS-
SPME) to extract amfepramone and other organic com-
pounds. HS-SPME offers enhanced purification for complex 
biological samples, ensures green chemistry by avoiding 
organic solvent use and efficiently couple with gas chroma-
tographic systems. Notwithstanding, the recoveries achieved 
by the HS–SPME pre-concentration technique were unsat-
isfactory. Other extraction methods also suffer significant 
limitations. SPE, especially, suffers analytic breakthrough 
when a large volume of samples is analysed [177]. Though 
being relatively simple, miniaturised and fast, LPME and 
SPME techniques are constrained with sample carry-over, 
year



































Fig. 2  Counterfeit over-the-counter (OTC) weight loss products 
reported in the US following FDA laboratory analysis. a Tainted 
anorectics reported in the US from April 2009 to December 2019. b 
Distribution of common dosage forms of OTC weight loss products 
in the US. c Undeclared pharmaceutically active ingredients detected 
in OTC weight loss products in the US [see supplementary material, 
Table S1]. DMMA 3,4-dimethoxy-N- methylamphetamine
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relatively high cost, the fragility of the fibre and relatively 
low accuracy [178, 179]. Given these limitations, developing 
new techniques with improved speed, safety, sensitivity, and 
reliability is of significant analytical interest. There is cur-
rently no consensus on a specific extraction/pre-concentra-
tion method for anorectic sample preparation. The different 
methods available in literature reflect the complexity of such 
counterfeited formulations and the target analytes.
Analytical methods for determination 
of counterfeit anorectics
Undeclared chemicals in slimming products or bodily fluids 
(such as blood or urine following exposure) can be analyti-
cally determined using several conventional methods. The 
most significant detection, identification and quantification 
of the parent drugs, analogues and/or metabolites are, how-
ever, achieved utilising the established techniques of liquid 
chromatography (LC) and gas chromatography (GC) cou-
pled with mass spectrometry (MS) and spectroscopic meth-
ods. Table 2 shows cases of weight loss formulation use, 
analytical determination techniques and clinical outcomes.
Liquid chromatography–mass spectrometry 
Liquid chromatography, coupled with mass spectrometry 
detection (LC–MS) has emerged as the preferred technique 
for identification and quantification of chemical entities in 
counterfeit and illegal pharmaceutical preparations [27, 
180]. Considering the analytical gold standard, the LC–MS 
has been extensively utilized due to the high separation 
power that facilitates application to complex mixtures, 
enhanced sensitivity and specificity without the need for 
derivatization, and it is currently a well-established presence 
in most laboratories worldwide for routine analyses. Follow-
ing separation via LC, the MS primarily enables conversion 
of analyte molecules to an ionized state, separating charged 
molecules according to their mass-to-charge ratio (m/z value) 
and subsequent identification as the charged species [181]. 
The foregoing thus enables targeted and untargeted screen-
ing of formulations, and in some instances, identification 
and/or structural elucidation of constituents of an unknown 
compound, when LC–MS is linked with infrared (IR) and 
nuclear magnetic resonance spectroscopy techniques [182].
Ultra-performance liquid chromatography (UPLC) pro-
vides a meaningful improvement over conventional LC and 
is especially useful for method development [170], where 
quick run times, including rapid response to alterations in 
column and mobile-phase conditions, are required. When 
linked to MS, UPLC is time-saving, offering improved per-
formance in resolution, sensitivity and precision [183, 184]. 
Stypulkowska et al. [185] utilized LC–MS to determine the 
sibutramine and its analogues in some herbal dietary sup-
plements. Similarly, undeclared rimonabant, sibutramine 
and their respective analogues were identified in imitated 
Acomplia [103]. In a survey of twenty-two herbal slim-
ming preparations, Wang et al. [34] developed an LC–MS 
method which facilitated the simultaneous determination of 
sibutramine (45.5%), N-monodesmethyl sibutramine (9.1%) 
and phenolphthalein (13.6%) in the samples analysed.
Liquid chromatography with tandem mass spectrometry 
(LC–MS/MS) has been applied for analytical profiling of 
counterfeit pharmaceuticals in recent years. By coupling 
LC and two MS connected in series, the method allows 
sample separation, ionization and characterization utilizing 
the m/z value and relative abundance [186]. Subsequently, 
LC–MS/MS enables analysis of complex matrices with 
optimum molecular specificity and detection sensitivity 
that allow structural identification of each constituent of the 
mixture [187]. Kim et al. [188] developed and validated an 
LC–MS/MS method for routine herbal dietary supplement 
adulteration screening for sibutramine and its metabolites. 
An LC–MS/MS method with the ability to screen synthetic 
adulterants from multiple pharmacological classes including 
anorectics (e.g., fenfluramine, methylphenidate, sibutramine) 
in herbal remedies was also developed by Bogusz et al. 
[189]. A similar technique applying LC–QTRAP–MS/
MS was used by Chen et al. [190] to determine blood pres-
sure and lipid-lowering agents, sedative drugs, antidiabetic 
drugs, weight-reducing agents and aphrodisiac compounds, 
in adulterated plant-based health supplements. Other ana-
lytical approaches to the analysis of counterfeited slimming 
phytotherapeutic formulations have been comprehensively 
reviewed by De Carvalho et al. [25].
Gas chromatography–mass spectrometry
The GC method has been used in the detection and charac-
terization of counterfeit medicines. When combined with 
mass spectrometry, GC–MS primary use lies with the analy-
sis of illegal pharmaceutical formulations in medicine con-
trol laboratories [32]. For example, GC–MS was utilized 
to determine anorectics, stimulants and benzodiazepines in 
counterfeit slimming drugs [32, 112]. Due to the nonvolatile 
and considerable hydrophilic nature of most pharmaceutical 
formulations, complex derivatization to their respective less 
polar compounds is often necessary to enhance their iden-
tification and quantitative analysis [169]. GC–tandem MS 
(GC–MS/MS) offers enhanced separation, higher precision 
and selectivity, and has been employed in profiling some 
anorectics in fake pharmaceuticals. Li et al. [191] developed 
a GC-electron ionization–MS/MS method to simultaneously 
detect seven adulterants, including the anorectics fenflu-
ramine, amfepramone and sibutramine in slimming func-
tional foods. In a recent study, and the first proof of concept, 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Arbouche et al. [192] developed a GC–MS/MS method to 
determine metformin in human hair following prolonged 
use of the antidiabetic drug. The sensitive technique showed 
limits of detection and quantification at 1 and 100 pg/mg 
hair, respectively, but illustrated the poor incorporation of 
metformin into human hair in comparison with other drugs.
Derivatization for GC–MS analysis depends on the 
chemical properties of specific anorectics. For example, 
pentafluoropropionic anhydride derivatization was employed 
for simultaneous screening of fenfluramine and phentermine 
in urine samples [142]. Similarly, Strano-Rossi et al. [169] 
detected metabolites of sibutramine in a study of its pat-
tern of fragmentation following derivatization to the cor-
responding methyl and trimethylsilyl derivatives. Arbouche 
et al. [192] and Goedecke et al. [193] used acylation reagent, 
N-methyl-bis(trifluoroacetamide) (MBTFA) derivatization 
and GC–MS to determine the metformin in hair and sur-
face water, respectively. A similar GC–MS approach, in 
combination with LC–diode array detection, was used by 
Liu et al. [194] to screen anorectics and other adulterants 
in 266 phytotherapeutic formulations. Unlike LC–MS, the 
derivatization requirement of GC–MS analysis makes the 
analytical procedure cumbersome and error-prone [195]. 
Current trends in analytical method development and vali-
dation are aimed at advancing simplicity and reducing time 
at each analytical stage while increasing analytical through-
put. The need to often change solvents increases complexity 
and extends sample preparation times. This makes GC–MS 
analysis process of counterfeit formulations inconsistent 
with current trends, despite its merits. However, the costs 
for GC–MS or GC–MS/MS instruments are relatively lower 
than those LC–MS/MS instruments at this time.
Capillary electrophoresis
Capillary electrophoresis (CE) has become a versatile sepa-
ration technique in contemporary biopharmaceutical analyt-
ics, albeit in a considerably smaller footprint as compared 
to GC and LC. Sample pre-concentration for CE allows for 
short analysis times, reduced volumes of the sample and 
reagents used, and high selectivity [196]. Two forms of CE, 
micellar electrokinetic chromatography [197] and capillary 
zone electrophoresis (CZE) [198] have been used as afford-
able alternatives for counterfeit pharmaceutical determina-
tion. Piette and Parmentier [199] utilised CZE to analyse 
amphetamine-based anorectics in seized formulations. While 
the conventional CE technique generally employs UV detec-
tors, hyphenation with MS detectors for highly resolved 
chemical and structural information of adulterants of weight 
loss pills and dietary supplements have been investigated as 
a potential confirmatory approach. Akamatsu and Mitsuhasi 
[200] and dos Santos et al. [201] developed CE–MS/MS 
methods to identify anorectics and other adulterants in some 
17Forensic Toxicology (2021) 39:1–25 
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phytotherapeutics, yielding limits of detections lower than 
0.06 µg L−1. As compared to LC, CE equipment and acces-
sories are cheaper, lasts longer, simple to use and requires 
minimal amounts of reagents and samples [202]. Further 
method development and validations are envisaged to offer 
CE as a robust option in fighting counterfeit drugs especially 
in developing countries.
Nanomaterials
Nanotechnology is a powerful tool that has demonstrated its 
usefulness in many fields, although more work needs still 
to be done to transfer the results from research to routine 
analysis. Nanomaterials are used in the dietary supplement 
industry to improve the drug delivery to target organs, tis-
sues or cells. The methods used for the determination of 
nanomaterials in dietary supplements have been reviewed, 
finding that CE is the technique of choice to determine dif-
ferent metal nanoparticles, such as gold, platinum or pal-
ladium [203].
The second use of nanomaterials deals with their use in 
the proposal of new analytical methods for the determination 
of anorectics, although it is still in the incipient stage. Sam-
ple preparation is one of the most challenging steps since 
most errors in the analytical process arise from this step. 
Carbon nanotubes (CNTs) have been used to determine met-
formin [204] and amphetamine-derived anorectics, including 
phentermine [205].
Magnetic multi-walled CNTs were used to produce a 
methacrylate-based molecularly imprinted polymer on their 
surface, where metformin was used as the template [204]. 
Some advantages of this polymer are the faster kinetics of 
sorption and desorption owing to the high surface area of 
nanomaterials, as well as the ease of operation owing to 
the magnetic properties of the nanomaterial that facilitates 
its separation from complex matrices during the extraction 
process. The method was applied to different spiked sam-
ples, such as urine, human serum, and sea, tap and mineral 
water, with extraction recovery percentages in the range of 
95.5–104.7%. Oxidized multi-walled CNTs have been used 
to coat SPME fibres for the microextraction of 7 ampheta-
mine-like stimulants in urine [205]. The oxidation of CNTs 
allows a higher surface area compared to bare CNTs, as well 
as the introduction of hydroxyl groups owing to the oxida-
tion process enhances the interaction with polar analytes.
The use of nanomaterials for the detection of anorectics 
has been more extensively used than for sample preparation. 
Although gold-based nanomaterials have been used for the 
determination of metformin alone [229] or in binary mix-
tures [230] and fenfluramine [231], the most important con-
tribution of nanomaterials to anorectic determination is their 
integration into electrochemical sensors [232–234]. Several 
sensors have been described for metformin determination, as 
amperometric sensors, using graphene/nanoflakes-polymeth-
ylene blue/fluorine doped tin oxide, nickel oxide nanotubes, 
nanostructured Fe-Cu/TiO2, a Cu metal–organic framework 
to modify surface of different electrodes [232], as well as 
zinc ferrite, copper oxide and gold nanoparticles have been 
successfully used to modify the surface of a glassy carbon 
electrode [233]. Impedimetric sensors have also been devel-
oped using nanomaterials, such as Prussian Blue nanocubes/
carbon nanospheres/fluorine doped tin oxide. The excellent 
features of nanomaterials, such as high surface-to-volume 
ratio and high conductivity, have provided high sensitiv-
ity and selectivity levels to the developed sensors. Screen-
printed electrodes have been integrated with CNTs to detect 
modafinil in saliva by adsorptive stripping voltammetry 
[234]. This constitutes one example on integrated analyti-
cal platform using nanomaterials and printing technologies, 
where CNTs are used as SPE sorbents prior to adsorptive 
stripping voltammetry. The integration of SPE and the 
printed electrochemical sensor constitutes a real advantage 
and ease the operation of the electrochemical sensor when 
the analysis of real samples is tackled.
Conclusions
Slimming formulations doped with anorectic cocktails to 
boost their weight-reducing effectiveness are not uncommon 
and present a global health and safety threat. The effects of 
such additives, often from multiple chemical classes on the 
human body, are unpredictable. This review has highlighted 
the current scope of anorectics generally found as adulter-
ants in weight-reducing formulations, including their mode 
of action and adverse effects on unsuspecting users. The 
limitations and mitigation strategies of conventional sample 
preparation / instrumental analyses have also been presented. 
While LC–MS(/MS) remains the gold standard for analytical 
profiling of such counterfeits, improved pre-concentration 
methods are required to facilitate rapid and quantitative 
identification of specific chemical constituents. Also, CE 
presents an essential alternative to LC and GC due to much 
lower cost in fighting anorectic adulteration in pharmaceu-
tical formulations. The incipient use of nanomaterials has 
opened new insights in sensor development as a powerful 
tool to screen for samples before proceeding to confirma-
tory analysis by LC–MS, GC–MS and CE. This summary 
of available literature also provides insight into the present 
state of research in profiling adulterants in counterfeit ano-
rectic products.
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